As state officials investigate reducing costs by leveraging their collective buying power to purchase prescription drugs, the National Academy for State Health Policy (NASHP) has developed a Checklist for Coordinating Public Purchasing of Prescription Drugs to help states establish baseline data across public purchasers and identify effective strategies to coordinate purchasing. The checklist is designed to […]
Author Archive for: jennifer-reck
About Jennifer Reck
Jennifer Reck, Project Director, joined NASHP in 2015. She has designed and implemented technical assistance for state learning collaboratives to advance 1) evidence-based policymaking through patient-centered outcomes research and 2) alternative payment models within federally qualified health centers. She directs evaluation teams related to Medicaid delivery system and payment reforms, including State Innovation Models, and leads dissemination efforts to engage states with findings from federal initiatives to advance evidence-based preventive care.
Prior to joining NASHP, Jennifer was Director of Grants Management for the Maine Medical Association (MMA) where she managed grants to engage physicians in payment reform as well as outreach and advocacy efforts to implement the Affordable Care Act. She also directed the MMA’s academic detailing program, the Maine Independent Clinical Information Service (MICIS), an educational outreach effort to promote evidence-based primary care. Prior to her time at the MMA, she worked as a Policy Analyst for Prescription Policy Choices, serving states with policy models and technical assistance to address quality and cost concerns related to prescription drugs, and as a Publishing Editor for Elsevier Science, managing their portfolio of health policy-related journals. She received her master’s degree from Cornell University in Science and Technology Studies and her bachelor’s degree in the History and Philosophy of Science from Bard College.
Entries by Jennifer Reck
The same drugs that appear on state transparency reports identifying costly drugs also appear in an independent research institute’s report on drugs whose rapidly rising prices were not supported by new clinical evidence on the drugs’ safety or efficacy. The Institute for Clinical and Economic Review (ICER), an independent research organization that objectively evaluates prescription […]
Last week, Nevada fined 21 pharmaceutical companies $17.4 million for failing to submit a report explaining recent, significant price hikes to essential diabetes drugs, as required by the state’s drug cost transparency law. Faced with drug price increases far outpacing rates of inflation, states across the country are enacting transparency laws designed to shed light […]
As health plans prepare to submit rate filings, a new report from Oregon’s Division of Financial Regulation’s Prescription Drug Price Transparency Program illuminates just how much prescription drug prices impact insurance premiums. To increase health care cost transparency, Oregon requires health insurance companies to report on the impact of prescription drug prices on insurance plan […]
Colorado and Michigan have joined Oklahoma to become the nation’s pioneering states with approved State Plan Amendments (SPAs) that enable Medicaid alternative payment models (APMs) for prescription drugs in the form of outcome-based contracts with pharmaceutical manufacturers. In early May, state experts from Oklahoma, Colorado, and Michigan shared their experiences implementing their APMs during a […]
States, as major purchasers of health care, have a compelling interest to spur primary care providers to adopt the latest research to improve the quality and cost-effectiveness of care. This new report, the third in the EvidenceNOW: Insights for State Health Policymakers Series, highlights policy levers states can use to support the adoption of evidence-based […]
As drug price transparency measures proliferate across states, the National Academy of State Health Policy (NASHP) has released revised model transparency legislation featuring a common data set to reduce reporter burden and yield standardized, actionable data that will be comparable across states. The data — to be reported by manufacturers, pharmacy benefit managers (PBMs), wholesalers, and insurers — will […]
The National Academy for State Health Policy (NASHP) provided a grant to the Colorado Department of Health Care Policy and Financing to develop a new payment methodology for physician-administered drugs (PADs). PADs are drugs delivered by intravenous infusion or injection in clinical settings. The category includes costly drugs, such as chemotherapy and other specialty medications. […]
Unrelenting and unpredictable increases in prescription drug prices have spurred states to try to unlock the black box of manufacturer pricing strategies by requiring disclosure of how prices are set and how rebates are handled throughout the supply chain. Six states already have transparency laws on their books and almost two dozen more have introduced […]
State policymakers must often take action during an emerging crisis even when evidence identifying the best policy approach is not be available. This report, Evidence-Based Policymaking Is an Iterative Process: A Case Study of Antipsychotic Use among Children in the Foster Care System, explores successful state responses to dramatic increases in antipsychotic prescription rates in Medicaid-enrolled children […]